Biosafe plant virus expression system for transient production of human papillomavirus oncoproteins and their use for therapeutic vaccine development
Project goals
The aim of the proposed project is to prepare protein immunogens derived from human papillomavirus HPV16 and optimization of their expression in plants for developing experimental therapeutic anti-HPV16 vaccines. We propose the production of different proteins containing immunodominant HPV16 epitopes from the E7 or E6 oncoproteins. We would like to develop the conditions leading to the high transient expression levels of heterologous proteins. The novelty of our attitude will be the new systems reliedon a deconstructed TMV and PVX replicon strategy, which allows a stringent containtment of the recombinant viruses and provides us with biosafe transient expression units. The used host plants will be transgenic and non-transgenic N. benthamiana, a nonfood and nonfeed. We propose a strategy of economical expression of pharmaceutical proteins using viral vectors with high biosafety containment and without Agrobacterium contamination. Immunogenicity of the produced proteins will be examined in a mouse model by the detection of specific humoral, cell-mediated, and anti-tumor immunity.
Keywords
transientní expreserostlinný virový vektorbezpečnostpapilloma virusonkoprotein
Public support
Provider
Czech Science Foundation
Programme
Standard projects
Call for proposals
Standardní projekty 12 (SGA02009GA-ST)
Main participants
—
Contest type
VS - Public tender
Contract ID
521/09/1525
Alternative language
Project name in Czech
Biologicky bezpečný expresní systém založený na rostlinných virech pro transientní expresi papillomavirových onkoproteinů a vývoj terapeutické vakcíny
Annotation in Czech
Cílem projektu je transientní exprese epitopů z onkoproteinů E6 a E7 lidského papillomaviru HPV16 v rostlinách pomocí dekonstruovaných virových vektorů a jejich využití k vývoji experimentálních vakcín pro terapii nádorů vyvolaných HPV16.
Scientific branches
R&D category
ZV - Basic research
CEP classification - main branch
EI - Biotechnology and bionics
CEP - secondary branch
FD - Oncology and haematology
CEP - another secondary branch
EE - Microbiology, virology
10606 - Microbiology
10607 - Virology
20801 - Environmental biotechnology
20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management
20803 - Environmental biotechnology related ethics
20901 - Industrial biotechnology
20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation
20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials
30204 - Oncology
30205 - Hematology
30401 - Health-related biotechnology
30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)
30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])
30404 - Biomaterials (as related to medical implants, devices, sensors)
30405 - Medical biotechnology related ethics
40401 - Agricultural biotechnology and food biotechnology
40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming
40403 - Agricultural biotechnology related ethics
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
The project gone according to plan both in terms of expertise and in terms of disbursement of funds.
Solution timeline
Realization period - beginning
Jan 1, 2009
Realization period - end
Dec 31, 2011
Project status
U - Finished project
Latest support payment
Apr 16, 2011
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP12-GA0-GA-U/02:2
Data delivery date
May 2, 2016
Finance
Total approved costs
4,792 thou. CZK
Public financial support
4,792 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
0 thou. CZK
Basic information
Recognised costs
4 792 CZK thou.
Public support
4 792 CZK thou.
100%
Provider
Czech Science Foundation
CEP
EI - Biotechnology and bionics
Solution period
01. 01. 2009 - 31. 12. 2011